You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)與華奧泰生物簽署藥品技術轉讓與合作開發合同
阿思達克 06-25 09:37

君實生物(01877.HK)公布,與上海華奧泰生物於6月24日簽署《藥品技術轉讓與合作開發合同》。根據協議約定,公司同意以9,000萬元人民幣從華奧泰生物受讓阿瓦斯汀單抗生物類似藥(項目代號「HOT-1010」)的現有研發成果及其後續技術支持。在藥品註冊成功後,藥品產生的全部營業利潤按公司和華奧泰生物各50%的比例分配。

HOT-1010是一款重組人源化抗血管內皮生長因子(VEGF)單克隆抗體注射液,已獲得國家藥監局核准簽發的《藥物臨床試驗批件》,處於臨床試驗I期階段。HOT-1010可以選擇性地與人血管內皮生長因子(VEGF)結合並阻斷其生物活性,主要用於治療轉移性結直腸癌和晚期、轉移性或復發性非小細胞肺癌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account